Profiting From the Biotech Boom

Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. [Outsider Club logo] Profiting From the Biotech Boom [Jason Simpkins Photo] By [Jason Simpkins]( Written May 14, 2021 Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. And whereas new medicine could often take 10 years to commercialize, complex avant-garde coronavirus vaccines charged through pipelines at record speed. Indeed, we've finally seen how quickly things can move, and what can truly be achieved when the government and private sector collaborate on a common, urgent goal. The results have been [a boon for humanity and investors](. Pfizer (NYSE: PFE) dug itself out of the COVID collapse, climbing 45% on the strength of its vaccine development. The company's success culminated in an massive earnings beat last week. [Silicon Valley’s Death Sentence]( Silicon Valley is facing ruin… Its decline has nothing to do with COVID-19 or political unrest. This is about same trap the Rust Belt fell into decades ago. But one off-radar company is expected to come out as the huge winner of this development. It discovered the answer to a problem that might be the final nail in Silicon Valley’s coffin. Institutional investors like Vanguard and BlackRock are [pouring billions into this company.]( We’re about to witness one of the biggest breakthroughs in the history of technology… You could set yourself up for 950%... 6,893%... or even an incredible 12,795% gain. [Exact details here.]( Pfizer reported earnings of $0.93 per share for the first quarter — a 47% surge from last year that easily topped the FactSet consensus estimate of $0.77 a share. Revenue rose 42% to $14.6 billion. More importantly, though, the company vastly increased its projected revenue from its COVID vaccine, saying it now expects $26 billion in sales this year, up from the $15 billion it had projected in February. It also expects to have the capacity to manufacture 3 billion doses of the vaccine in 2022, and is negotiating contracts with governments for supply in 2022 and beyond. [Pfizer Covid Timeline] The company has a plethora of other remedies in the works as well. As a result, Pfizer raised its full year guidance, and is now projecting between $70.5 billion to $72.5 billion in annual revenue and net earnings of $3.55 to $3.65 per share. BioNTech (NASDAQ: BNTX), Pfizer's partner on the COVID vaccine, has done even better for itself, having already surged 114% this year. It also beat earnings estimates with eye-popping growth figures. Earnings per share rose 2,134.62% over the past year to $5.29, while revenue jumped 7,995.18% to $2.5 billion. Astonishing when you consider the company was losing money a year ago. Get Ready for Huge Fed Move (As Soon as June 16) Federal Reserve Chairman Jerome Powell just broke HUGE news... After months of silence, he finally admitted that the Fed is working on a digital dollar. This bombshell move could spell disaster for Bitcoin. But if you know how to position yourself, you could multiply your money by as much as 60 times in the months ahead. I expect truly historic windfalls with a “digital dollar” going live — some investors have already pocketed gains of as much as 1,585%, and that’s just the start. It’s vital you act BEFORE the Fed makes its next big announcement. [Click here for everything you need to know.]( But now the company has signed contracts to deliver 1.8 billion doses of its COVID vaccine in 2021. That would generate more than $15 billion in sales, which is well ahead of BioNTech stock analysts' forecast for $10.5 billion in full-year sales. Better still, BioNTech believes its vaccine will work against India’s vicious “double mutant” strain of COVID. The company has tested its two-dose vaccine, which is currently not available in India, against similar “double mutants” and researchers are confident their shot will still be protective based on the data. And, as with Pfizer, BioNTech raised its guidance and pointed to other promising initiatives. It's expanding with a new mRNA manufacturing plant in Singapore that will manufacture hundreds of millions of doses of mRNA-based vaccines each year. Besides its mRNA-based vaccines, BioNTech also has a pipeline of cancer programs and infectious disease programs. [Biontech Pipeline]So, again, if you think companies like Pfizer and BioNTech will recede along with the threat of COVID, think again. And on top of that there's a host of other companies joining them in this bold, new 21st-century biotech boom. Of course, investing in the sector isn't always as easy as singling out stocks like these. [Dr. Fauci Backs New COVID Technology (20-cent stock to soar)]( Incredibly enough, Dr. Anthony Fauci is backing a new COVID-fighting technology. He says it merits “serious consideration” and even uses it himself. It’s not a vaccine, but that hasn’t stopped other experts from getting behind it... The Centers for Disease Control (CDC) just greenlighted this device or reopening schools and businesses. And the FDA is on board too, lifting regulatory restrictions to deploy this everywhere. One tiny tech stock owns all of the patents on this technology. For a brief window, you can buy it for $0.20 per share. [Click here for the full story.]( It takes great attention to detail, the ability to monitor drug development, and a full understanding of the catalysts that propel biotech stocks to big-time gains. That's the only way to truly maximize your profit — not just ride some coattails after the fact. Fortunately my friend, colleague, and renowned biotech expert Keith Kohl has developed a simple system that can easily hand even the most novice biotech investor double- and triple-digit profits. In fact, if you're capable of reading a calendar, then guess what? You're qualified. It's that easy to isolate life-changing gains in this seemingly byzantine sector. And I can prove it. Keith is hosting [a special, one-time training event on May 20]( (next Thursday) in which he'll provide all of the details. And it's completely FREE. You literally have nothing to lose, and everything to gain. You're not going to find a better breakdown of the biotech sector anywhere. And the profit potential is enormous. [So check out the details here](. Fight on, [Jason Simpkins Signature] Jason Simpkins [follow basic]([@OCSimpkins on Twitter]( Jason Simpkins is Assistant Managing Editor of the Outsider Club and Investment Director of The Wealth Warrior, a financial advisory focused on security companies and defense contractors. For more on Jason, check out his editor's [page](. *Follow Outsider Club on [Facebook]( and [Twitter](. Browse Our Archives [Cut the Fed Some Slack]( [The Fed’s “Three Mandates” Suffer From the “Three Body Problem”]( [Inflation as Transitory as "Toilet Paper Shortages?" Not in the Real World]( [Guns, Pirates, and Treasure Hunts]( [Markets Preparing for Hyperinflation]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Outsider Club, please add newsletter@outsiderclub.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Outsider Club](, Copyright © 2021, [Angel Publishing LLC]( & Outsider Club LLC, 3 E Read Street Baltimore, MD 21202. For Customer Service, please call (855) 496-0830. All rights reserved. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. Angel Publishing and Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. This letter is not intended to meet your specific individual investment needs and it is not tailored to your personal financial situation. Nothing contained herein constitutes, is intended, or deemed to be – either implied or otherwise – investment advice. Neither the publisher nor the editors are registered investment advisors. This letter reflects the personal views and opinions of the editors of Outsider Club and that is all it purports to be. While the information herein is believed to be accurate and reliable it is not guaranteed or implied to be so. Neither the editors of Outsider Club, nor anyone else, accepts any responsibility, or assumes any liability, whatsoever, for any direct, indirect or consequential loss arising from the use of the information in this letter. The information contained herein is subject to change without notice, may become outdated and may not be updated. The editors of Outsider Club, entities that they control, family, friends, employees, associates, and others may have positions in securities mentioned, or discussed, in this letter. No part of this letter/article may be reproduced, copied, emailed, faxed, or distributed (in any form) without the express written permission of the Outsider Club. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.